Towards an HIV Cure: Understanding HIV Persistence and Therapeutic Approaches

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor of Medicine, The University of Melbourne
Consultant infectious diseases physician, Royal Melbourne Hospital and Alfred Hospitals
Melbourne, Australia

President, International AIDS Society (IAS)
International co-chair IAS2023, Brisbane Australia and AIDS2024, Munich, Germany

CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:Top of page

Professor Sharon Lewin is an infectious diseases physician and basic scientist, who is internationally renowned for her research into all aspects of HIV disease and specifically in strategies to achieve an HIV cure. She received her medical degree and PhD from Monash University, Melbourne, Australia and post-doctoral training at Rockefeller University, New York. She is the Director of the Doherty Institute, a joint venture of the University of Melbourne and Royal Melbourne Hospital and Melbourne Laureate Professor of Medicine at the University of Melbourne, Melbourne, Australia. In 2022, she became the inaugural director of the Cumming Global Centre for Pandemic Therapeutics, a new centre at the Doherty Institute established by a philanthropic gift of $250 million from Canadian philanthropist Geoff Cumming and $75 million from the Victorian government. She leads Australia’s national research network on pandemic preparedness, called APPRISE, which includes >100 investigators. She heads a laboratory of 25 scientists and clinicians working on basic and translational research and early phase clinical trials aimed at finding a cure for HIV. In 2019, She was appointed an Officer of the Order of Australia (AO) in recognition of her distinguished service to medical research, and to education and clinical care, in the field of infectious diseases, particularly HIV and AIDS.

Learning Objectives: Top of page

At the completion of this educational activity learners will:
1. Understand HIV latency and how HIV persists on ART.
2. Know about new assays that can quantify low levels of HIV in people on ART.
3. Be aware of new clinical trials in immunotherapy to achieve an HIV cure.
4. Know about the advances in gene therapy relevant to HIV cure.

CME Information:Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for September 13, 2023, as a live activity. This activity will also be available as an enduring activity from September 20, 2023, through September 12, 2026.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Planner) has no relevant financial relationships to disclose.
- Dr. Sanjiv S. Shah (Moderator) has no relevant financial relationships to disclose.
- Dr. Sharon R. Lewin (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Advisory Board Member with Gilead, AbbVie, Merck, Esfam, Immunocure, and Linkinvax. Dr. Lewin submitted her slides in advance for adequate peer review and supported her presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register